Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia

被引:1
作者
Zhang, Qi [1 ]
Zhang, Chun-Hong [2 ]
Wang, Zhen-Dong [3 ]
Wang, Dong [4 ]
机构
[1] Mudanjiang Univ, Affiliated Hosp 2, Publ Sect, Mudanjiang, Peoples R China
[2] Mudanjiang Univ, Affiliated Hosp 2, Dept Urol Surg, Mudanjiang, Peoples R China
[3] Mudanjiang Univ, Affiliated Hosp 2, Dept ENT Surg, Mudanjiang, Peoples R China
[4] Mudanjiang Univ, Affiliated Hosp 2, Dept Hematol & Rheumatol, 15 Dongxiaoyun St, Aimin Dist 157000, Mudanjiang, Peoples R China
来源
TUMORI JOURNAL | 2022年 / 108卷 / 02期
关键词
Acute lymphoblastic leukemia; adult; daunorubicin; idarubicin; ADOLESCENTS; CHILDREN;
D O I
10.1177/03008916211032724
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Anthracyclines are dispensable components of chemotherapy of patients with acute lymphoblastic leukemia (ALL). Objective: To analyze the efficacy and safety of induction with idarubicin (IDA) or liposoma daunorubicin (L-DNR) in treatment of adults with high-risk ALL (HR-ALL) (presence of mixed lineage leukemia gene [MLL] rearrangements, t[1;19], or prednisone poor response). Methods: Among 58 enrolled patients, 29 cases were defined as the IDA group and the other 29 patients were put into the L-DNR group. Both overall survival (OS) and progression-free survival (PFS) were estimated and overall response rate (ORR) was compared between the groups. Results: The L-DNR group's OS and PFS were insignificantly higher than in the IDA group (P=0.261 and P=0.247). Although not significantly different, the ORR of adults with HR-ALL receiving L-DNR regimens was also higher than in the IDA group (P=0.085). Comprehensive cytogenetic analysis revealed that patients harboring MLL rearrangement, E2A-PBX1, and P53 mutation had poorer prognosis than others. All 58 patients experienced hematologic response in this study; however, the length of hematologic response in the IDA group was significantly longer than in the L-DNR group (P=0.005). The incidence of bleeding and infection was without significant difference between the groups (both P>0.05). Conclusion: L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL. Patients with E2A-PBX1 are much more sensitive to L-DNR than IDA. Despite some progress made, outcomes in MLL rearrangement or P53 mutation carriers remain unsatisfactory, and intensive treatment will be critical.
引用
收藏
页码:182 / 188
页数:7
相关论文
共 11 条
  • [1] Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation
    Adige, Sunil
    Lapidus, Rena G.
    Carter-Cooper, Brandon A.
    Duffy, Alison
    Patzke, Ciera
    Law, Jennie Y.
    Baer, Maria R.
    Ambulos, Nicholas P.
    Zou, Ying
    Bentzen, Soren M.
    Emadi, Ashkan
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1105 - 1112
  • [2] Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults?: Comparison of the French FRALLE-93 and LALA-94 trials
    Boissel, N
    Auclerc, MF
    Lhéritier, V
    Perel, Y
    Thomas, X
    Leblanc, T
    Rousselot, P
    Cayuela, JM
    Gabert, J
    Fegueux, N
    Piguet, C
    Huguet-Rigal, F
    Berthou, C
    Boiron, JM
    Poutos, C
    Michel, G
    Fière, D
    Leverger, G
    Dombret, H
    Baruchel, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 774 - 780
  • [3] Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004
    Creutzig, Ursula
    Zimmermann, Martin
    Bourquin, Jean-Pierre
    Dworzak, Michael N.
    Fleischhack, Gudrun
    Graf, Norbert
    Klingebiel, Thomas
    Kremens, Bernhard
    Lehrnbecher, Thomas
    von Neuhoff, Christine
    Ritter, Joerg
    Sander, Annette
    Schrauder, Andre
    von Stackelberg, Arend
    Stary, Jan
    Reinhardt, Dirk
    [J]. BLOOD, 2013, 122 (01) : 37 - 43
  • [4] MLL-Rearranged Acute Lymphoblastic Leukemia
    El Chaer, Firas
    Keng, Michael
    Ballen, Karen K.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (02) : 83 - 89
  • [5] Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
    Eschenhagen, Thomas
    Force, Thomas
    Ewer, Michael S.
    de Keulenaer, Gilles W.
    Suter, Thomas M.
    Anker, Stefan D.
    Avkiran, Metin
    de Azambuja, Evandro
    Balligand, Jean-Luc
    Brutsaert, Dirk L.
    Condorelli, Gianluigi
    Hansen, Arne
    Heymans, Stephane
    Hill, Joseph A.
    Hirsch, Emilio
    Hilfiker-Kleiner, Denise
    Janssens, Stefan
    de Jong, Steven
    Neubauer, Gitte
    Pieske, Burkert
    Ponikowski, Piotr
    Pirmohamed, Munir
    Rauchhaus, Mathias
    Sawyer, Douglas
    Sugden, Peter H.
    Wojta, Johann
    Zannad, Faiez
    Shah, Ajay M.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (01) : 1 - 10
  • [6] Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol
    Haiat, Stephanie
    Marjanovic, Zora
    Lapusan, Simona
    Vekhoff, Anne
    Rio, Bernard
    Corre, Elise
    Dimicoli, Sophie
    Hirsch, Pierre
    Marie, Jean-Pierre
    Legrand, Ollvier
    [J]. LEUKEMIA RESEARCH, 2011, 35 (01) : 66 - 72
  • [7] Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 x 109/l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group
    Hastings, Caroline
    Gaynon, Paul S.
    Nachman, James B.
    Sather, Harland N.
    Lu, Xiaomin
    Devidas, Meenakshi
    Seibel, Nita L.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (04) : 533 - 546
  • [8] The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
    Hong, Yan
    Zhao, Xiaosu
    Qin, Yazhen
    Zhou, Songhai
    Chang, Yingjun
    Wang, Yu
    Zhang, Xiaohui
    Xu, Lanping
    Huang, Xiaojun
    [J]. ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1547 - 1554
  • [9] The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
    Li, Xi
    Xu, ShuangNian
    Tan, Ya
    Chen, JiePing
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (06):
  • [10] Approach to the Adult Acute Lymphoblastic Leukemia Patient
    Sas, Valentina
    Moisoiu, Vlad
    Teodorescu, Patric
    Tranca, Sebastian
    Pop, Laura
    Iluta, Sabina
    Pasca, Sergiu
    Blag, Cristina
    Man, Sorin
    Roman, Andrei
    Constantinescu, Catalin
    Rus, Ioana
    Buse, Mihail
    Fetica, Bogdan
    Marian, Mirela
    Selicean, Cristina
    Berindan-Neagoe, Ioana
    Petrushev, Bobe
    Bumbea, Horia
    Tanase, Alina
    Zdrenghea, Mihnea
    Fuji, Shigeo
    Kitano, Shigehisa
    Tomuleasa, Ciprian
    [J]. JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)